[1]
Falkman L., Sundin A., Skogseid B., Botling J., Bernardo Y., Wallin G., Zhang L., Welin S., Lase I., Mollazadegan K. and Crona J. 2024. Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors. Upsala Journal of Medical Sciences. 129, S1 (Apr. 2024), e10660. DOI:https://doi.org/10.48101/ujms.v129.10660.